A single-arm, multicenter, open-label phase II trial of neoadjuvant treatment of darolutamide plus androgen deprivation therapy (ADT) for patients with locally advanced prostate cancer
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Darolutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 15 Jan 2025 Status changed to completed, according to Results published in the World Journal of Urology.
- 03 Jan 2025 Results published in the World Journal of Urology